Capitalizing a cure : how finance controls the price and value of medicines /

Mostrar otras versiones (2)

"Capitalizing a Cure takes us into the struggle over accessing a medical breakthrough to investigate the power of finance over business, biomedicine, and public health. When sofosbuvir-based medicines launched in 2013, they promised a cure for millions of patients worldwide with hepatitis C. Bu...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor principal: Roy, Victor, 1986- (Autor)
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Oakland, California : University of California Press, [2023]
Temas:
Gilead Sciences (Firm)
Drugs > Prices > United States.
Pharmaceutical industry > Economic aspects > United States.
Drug development > Economic aspects > United States.
Sofosbuvir > Prices > United States.
Hepatitis C > Treatment > Prices > United States.
Médicaments > Prix > États-Unis.
Industrie pharmaceutique > Aspect économique > États-Unis.
Médicaments > Développement > Aspect économique > États-Unis.
Hépatite C > Traitement > Prix > États-Unis.
Drugs > Prices
Pharmaceutical industry > Economic aspects
United States
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Preface : pandemics, Wall Street, and the value playbook
  • Introduction : the politics of drug pricing and the value of a cure
  • Capitalizing science : public knowledge into pharmaceutical assets
  • Capitalizing drugs : shareholder power and the cannibalizing company
  • Capitalizing health : the struggle over value and treatment access
  • From financialization to public purpose for health
  • Conclusion : reckoning with pharmaceutical value in crisis times.

Ejemplares similares